TLV •
Healthcare •
Biotechnology •
Quote as of 07/28/2026 17:24
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeTLV
Market Capitalization36.55 mln
Float2,499 mln
Earnings Date08/14/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
10.11
Highly suspicious
Relative Strength
53
/ 100
Slightly ahead
Debt / Equity
0.54
Moderate leverage
ROE
-41.45
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Founded in 2003 and based in Israel, BioLineRx is a drug development company focused on cancer and rare diseases. Its leading programs include an oral cancer treatment targeting DNA damage mechanisms in brain tumors and other cancers, a peptide-based therapy being studied across multiple conditions including sickle cell disease and pancreatic cancer, and a non-surgical skin lesion removal product. The company has completed a major late-stage clinical trial for multiple myeloma and continues to advance a broad range of treatments through various stages of development.
